Skip to main content
Equibles

NSRX · Nasus Pharma Ltd · Metrics

Track NSRX — free

Use NSRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NSRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.35 +0.03 (+0.90%)
Rebalance outlook locked
Market Cap
$38.89M
Shares
11.71M
Volume · Oct 28 4441 Avg daily vol (3M) 17.84K

NSRX metrics

52 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.32
Market cap
$38.89M

Price action

20 metrics
Price change (1W)
+2.5%
Price change (30D)
-7.5%
Price change (3M)
+9.6%
Price change (6M)
+14.1%
Price change (YTD)
-63.7%
Price change (1Y)
-58.2%
Trailing year
Price change (5Y)
—
52-week high
$9.15
52-week low
$2.01
Change from 52-week high
-63.7%
Change from 52-week low
+65.2%
Annualized volatility
104.5%
Annualized volatility (3M)
63.4%
Beta
0.7
RSI (14D)
45.9
Price vs SMA 50
-8.1%
Price vs SMA 200
-10.7%
Avg volume (3M)
17,839
Relative volume
0.6
Average dollar volume
$63,348

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
11.71M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.7
reciprocal yield 26.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-25.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-0.4%
Trailing 12 months
Net margin
-0.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$10.13M
Net income (TTM)
−$10.55M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.31

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-95.9%
Return on assets
-84.7%
Debt / equity
—
Current ratio
8.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
8.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$7.82M
Total assets
$12.45M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$10.52M
Capital expenditures (TTM)
—
R&D (TTM)
$4.54M
SG&A (TTM)
—
Stock compensation (TTM)
$810,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
10
13F filer change QoQ
+1
Institutional ownership
18.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-1.1%
Holder tenure
2.0
Price vs estimated holder cost
-31.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.7%
Latest settlement · 4.7 days to cover
Days to cover
4.7d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 2029039 CUSIP M7071P109 Visit website Investor relations